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It has been suggested that bacterial resistance is selected within a mutation selection
window of antibiotics. More recent studies showed that even extremely low concentration
of antibiotic could select resistant bacteria in vitro. Yet little is known about the exact
antibiotic concentration range that can effectively select for resistant organisms in animal
gastrointestinal (GI) tract. In this study, the effect of different dosages of enroﬂoxacin on
resistance andmutation development in rat GI tract E. coli was investigated by determining
the number of resistant E. coli recoverable from rat fecal samples. Our data showed that
high dose antibiotic treatment could effectively eliminate E. coli with single gyrA mutation
in the early course of treatment, yet the eradication effects diminished upon prolonged
treatment. Therapeutic and sub-therapeutic dose (1/10 and 1/100 of therapeutic doses)
of enroﬂoxacin could effectively select for mutation in GI tract E. coli at the later course
of enroﬂoxacin treatment and during the cessation periods. Surprisingly, very low dose
of enroﬂoxacin (1/1000 therapeutic dose) could also select for mutation in GI tract E.
coli at the later course of enroﬂoxacin treatment, only with slightly lower efﬁciency. No
enroﬂoxacin-resistant E. coli could be selected at all test levels of enroﬂoxacin during long
term treatment and the strength of antibiotic treatment does not alter the overall level of
E. coli in rat GI tract. This study demonstrated that long term antibiotic treatment seems
to be the major trigger for the development of target mutations in GI tract E. coli, which
provided insight into the rational use of antibiotics in animal husbandry.
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INTRODUCTION
The use of antibiotics in treatment of bacterial infections repre-
sents one of the most important inventions in human history.
Since its discovery in the 1940s, antibiotics have saved millions of
human lives and have also been widely used in the ﬁelds of veteri-
nary medicine and agriculture in the past 70 years. However, due
to the extensive use and misuse of antibiotics in various settings,
most agents have lost their efﬁcacy to bacteria as a result of emer-
gence and spread of multiple-drug-resistant bacterial pathogens
(Ferber, 2010). In the last decade, resistance to human ﬁrst line
drugs has increased signiﬁcantly and the choices of treatment for
serious bacterial infections have become extremely limited, threat-
ening to take medicine back into the pre-antibiotic era (Hawkes
et al., 2007; Brazier, 2008; Ferber, 2010; Srivastava et al., 2011;
Ghafur, 2013).
The mechanisms of antimicrobial resistance in bacteria have
been intensively investigated (Tenover, 2006). To date, the mech-
anisms of bacterial resistance to any antibiotic has been known
to a certain extent. However, the driving forces mediating the
selection and development of antibiotic resistance in bacteria as
well as how resistance genes spread between different organisms
and environment niches are complex and still not completely
understood. Since resistance to antibiotics in bacteria has been
evolving over a long period of time, a complex repertoire of resis-
tance mechanisms have emerged. At this stage, it is still not clear
whether mutation development or acquisition of antimicrobial
resistance genes is the primary mechanism which is required to
initiate the development of antimicrobial resistance in a bacterial
population. Nevertheless, a wide range of transferable elements
harboring antimicrobial resistance genes is known to be responsi-
ble for the rapid disseminationof resistance traits in bacteria (Zhao
et al., 2010; Jiang et al., 2011; Zheng et al., 2012; Yang et al., 2014).
Regardless of the nature of resistance mechanism, acquisition of
antimicrobial resistance genes or genetic mutations responsible
for bacterial antibiotic resistance, constant antibiotic pressure is
commonly accepted to be the driving force of expansion of the
resistant population. It has been suggested that resistant bacte-
ria were selected at the concentration of antibiotics within the
mutation selection window, a concentration between the minimal
inhibitory concentration (MIC) and minimal mutation preven-
tion concentration (MPC; Zhao and Drlica, 2002; Blondeau, 2009;
Firsov et al., 2013). However, recent studies have shown that
resistant bacteria can be selected at very low concentration of
antibiotics in vitro. The concentration can be even lower than
the concentration of antibiotics used for growth promotion pur-
pose in animals, and the concentrationof environmental antibiotic
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residues due to natural production bymicroorganisms and human
contamination (Gullberg et al., 2011). However, these studies were
conducted in in vitro model and could not explain how ani-
mal GI tract organisms respond to different concentrations of
antibiotics, since growth promotional usage of antibiotics in ani-
mals is considered as the most important practice that selected
for both antibiotic-resistant genes and bacterial pathogens (Kelly
et al., 2004; Marshall and Levy, 2011; Looft et al., 2012). Ani-
mal GI tract is considered as a more complicated environment
than any other ecosystems. Recent studies have demonstrated the
role of bacterial stress responses in antibiotic resistance develop-
ment (Srinivasan et al., 2012; Bernier et al., 2013; Duval and Lister,
2013). The environmental stresses that the bacteria encountermay
lead to variation in physiological functions of the organisms, elic-
iting changes in the intrinsic mutation rate and abilities to survive
drug action (Poole, 2012). Animal GI tract imposes a mixture
of stresses to bacteria including low pH, oxidative stress, starva-
tion stress, antimicrobial compounds, and interactions between
microbiota, which may inﬂuence the development of antibiotic
resistance in GI tract ﬂora (Nguyen et al., 2011; Bernier et al.,
2013). However, in contrast to in vitro condition, the physiolog-
ical changes and ﬁtness costs arisen during the response to these
stresses and the development of mutations may in turn put the GI
tract bacteria under adverse conditions which may affect the sur-
vival ﬁtness of such organisms in the GI tract environment. The
effect of these factors on the development of antimicrobial resis-
tance in GI tract bacteria is not fully understood. In this study, a
rat model was used to test the effect of different concentrations
of antibiotics on the resistance development in E. coli in animal
GI tract.
MATERIALS AND METHODS
ANTIBIOTIC AND ANIMALS
Enroﬂoxacin was purchased from Sangon Biotech company
(Shanghai, China). The antibiotic was dissolved in 0.1 M NaOH
at 10 mg/mL stock solution on the day of use. 11–15 weeks old,
speciﬁed pathogen-free (SPF)male SD rats with body weight 250–
350 g were used in all experiments. Animals were purchased from
Guangdong Medical Laboratory Animal Center and were housed
individually and allowed free access to food and water. They were
examined twice every day for any clinical signs such as behav-
ior, gastrointestinal (GI) function, respiratory distress, food, and
water intake etc. The experimental protocol was approved by the
Research Animal Care and Use Committee of the Hong Kong
Polytechnic University.
ANTIMICROBIAL TREATMENT
Since ﬂuoroquinolones are concentration-dependent antibiotic
(Firsov et al., 2004), we checked the effect of different dosages of
ﬂuoroquinolone on the development of resistance to enroﬂoxacin
in E. coli in animal GI tracts. Thirty male rats were equally divided
into six groups: one group was treated with therapeutic dose of
enroﬂoxacin (10 mg/kg body weight), one was treated with saline
as control and other groups were treated with doses of 10-fold,
1/10, 1/100, and 1/1000 of the therapeutic dose.
The oral antibiotic treatment regimen lasted about 1 month
including three antibiotic treatments and three cessation gaps
between treatments. All the rats were subjected to different doses
of enroﬂoxacin treatment for 5 days, then cessation of antibiotic
treatment for 4 days, another enroﬂoxacin retreatment for 5 days,
followed by another cessation of antibiotic treatment for 8 days,
then enroﬂoxacin retreatment for another 5 days, and tracing for
3 more days without antibiotic treatment.
At the indicated time intervals, fresh feces (250–500 mg) were
collected and re-suspended in 1 ml of saline. The suspension was
mixed and diluted by 10-fold in saline. 100 μl of suspension
was plated on MacConkey agar containing 0 mg/L, 0.125 mg/L,
0.5 mg/L, and 2 mg/L of enroﬂoxacin. The plates were incubated
at 37◦C for 12 h and the total colony counts were recorded. The
colony forming units (CFUs) per gram of feces were determined.
Colonies that showed typicalmorphology of E. coli onMacConkey
plate (pink to rose-red, large regular colonies) were consid-
ered as E. coli and some of which were conﬁrmed by 16SrRNA
sequencing using primers (F: CCAGACTCCTACGGGAGGCAG,
R:CGTATTACCGCGGCTGCTG).
ANTIMICROBIAL SUSCEPTIBILITY
Antimicrobial susceptibilities to enroﬂoxacin were determined by
the agar dilution method in accordance with Clinical and Lab-
oratory Standards Institute guidelines (CLSI, 2013) using E. coli
strain ATCC 25922 as quality control. The MICs of enroﬂoxacin
were determined following CLSI guidelines (CLSI, 2013).
DETERMINATION OF THE TARGET MUTATION IN E. coli
Presence of target mutations of the Quinolone-resistance deter-
mining regions (QRDR) of the gyrA and parC genes in E. coli were
determined by PCR as previously described (Everett et al., 1996).
RESULTS
Thirty SPF male SD rats were selected for this experiment. Resis-
tance background of GI tract E. coli of these rats were checked by
plating 200∼300 mg of fecal samples of the rats on MacConkey
plates with 0, 0.125, 0.5, and 2 mg/L of enroﬂoxacin. All rats were
found to contain a similar amount of E. coli in their GI tract (data
not shown). Five rats exhibited a background of less susceptible
E. coli which can grow on MacConkey plate containing 0.5 mg/L
of enroﬂoxacin. No fecal E. coli was able to grow on MacConkey
plate with 2mg/L concentration of enroﬂoxacin (data not shown).
Twenty colonies with typical morphology of E. coli from Mac-
Conkey plates were randomly selected and conﬁrmed to be E. coli
by 16SrRNA sequencing. Similar E. coli conﬁrmation was per-
formed for the following each group of experiment by randomly
selecting 20∼40 E. coli for 16SrRNA sequencing. All the checked
colonies were conﬁrmed to be E. coli (data not shown).
Upon background check, these rats were separated into six
experimental groups. All ﬁve rats with a low background of E. coli
with reduced susceptibility to enroﬂoxacin were grouped into one
category and treatedwith ahighdose of enroﬂoxacin (10-fold ther-
apeutic dose). The rest of the 25 rats were randomly separated into
5 groups with one control group and 4 different treatment groups
including therapeutic dose, 1/10, 1/100, and 1/1000 of the thera-
peutic dose treatments. The background of the high dose group
animals is different from the others. The purpose of the high dose
group study is different from other groups and intended to check
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the efﬁciency of higher dose of enroﬂoxacin on the clearance of
less susceptible E. coli in animal GI tract.
EFFECT OF HIGH DOSE OF ANTIBIOTIC TREATMENT ON RAT GI TRACT
E. coli
For the 10-fold therapeutic dose treatment group, the application
of enroﬂoxacin caused gradual eradication of rat GI tract E. coli.
The numbers of GI tract E. coli decreased gradually during the
ﬁrst three days of treatment; the reduction became dramatic at
the fourth day of treatment and the number of E coli recoverable
remained at a low level for the ﬁrst treatment period. After with-
drawing the antibiotics, E. coli appeared again at the second day
after the cessation of antibiotic treatment and increased on the
third and fourth day. At the beginning of the second course of
treatment period, the numbers of GI tract E. coli almost returned
back to the normal level. During the whole 5-days antibiotic treat-
ment, the numbers of GI tract E. coli were not affected, and
remained at the normal level, which lasted throughout the second
antibiotic cessation period. TheGI tract E. coli gradually decreased
again upon the start of the third antibiotic treatment. The number
of E. coli became dramatically reduced again at the third day of
the third course of the treatment and then gradually recovered at
the fourth and ﬁfth days of the antibiotic treatment. The number
of E. coli kept recovering upon cessation of antibiotic treatment
(Figure 1Ai).
The effect of the antibiotic treatment to the development
of ﬂuoroquinolone-resistant E. coli was recorded. The num-
ber of less susceptible E. coli, which can grow at MacConkey
plate with 0.125 mg/L was high before antibiotic treatment and
slightly decreased on the second and third days of antibiotic
treatment. The number of less susceptible E. coli became dra-
matically decreased on the fourth and ﬁfth days of treatment.
After withdrawing the antibiotic, the number of less susceptible
E. coli reverted back to the normal level and remained so until
the beginning the third course of the antibiotic treatment. The
less susceptible E. coli slightly decreased at the ﬁrst day of the
third course of the antibiotic treatment and became undetectable
at the third day of the treatment, then recovered to normal level
throughout the rest of the treatment and non-treatment period
(Figure 1Aii).
The E. coli that can grow on MacConkey with 0.5 mg/L
enroﬂoxacin exhibiteddifferent response tohighdose enroﬂoxacin
treatment. The numbers of E. coli that can grow on MacConkey
with 0.5 mg/L enroﬂoxacin reduced on the seconf day of treat-
ment and became almost undetectable throughout the rest of
the ﬁrst, second and third treatments and non-antibiotic treat-
ment period except for a period of brief appearance during the
later course of the third treatment and antibiotic cessation period
(Figure 1Aiii). Throughout the whole course of treatment, no
E. coli isolates could be recovered onMacConkey platewith 2mg/L
of enroﬂoxacin, suggesting that high dose antibiotic could not
select for ﬂuoroquinolone-resistant GI tract E. coli.
Each of 20 E. coli isolates that grew on MacConkey with
0.125 mg/L and 0.5 mg/L enroﬂoxacin, respectively, were selected
to check theirMICand targetmutationproﬁles. E. coli that grewon
MacConkey with 0.125 mg/L enroﬂoxacin exhibited a MIC range
of enroﬂoxacin of 0.006∼0.03 with no mutation in any of the
four target genes gyrA, gyrB, parC, and parE; yet all E. coli strains
that grew on MacConkey with 0.5 mg/L enroﬂoxacin exhibited
MIC of enroﬂoxacin of 0.25∼1mg/L with single mutation in gyrA
(S83L; Table 1). Therefore, the MacConkey plate with 0.5 mg/L
enroﬂoxacin could be used to check for the mutation rate of GI
tract E. coli upon antibiotic treatment.
EFFECT OF THERAPEUTIC DOSE OF ANTIBIOTIC TREATMENT ON RAT GI
TRACT E. coli
For the therapeutic treatment group, the GI tract E. coli exhibited
slightly less susceptible E. coli background. Hence the therapeutic
treatment dose of enroﬂoxacin did not have any effect on the num-
bers of E. coli in rat GI tract (Figure 1Bi). However, after antibiotic
treatment, the number of less susceptible E. coli decreased slightly
and then increased to high level throughout the ﬁrst course of
antibiotic treatment and antibiotic cessation periods. During the
second course of treatment, the numbers of less susceptible E.
coli reduced gradually during treatment and remained at a lower
level during the second antibiotic withdrawal period. During the
third course of antibiotic treatment, the number of less susceptible
E. coli increased to a high level and remained so until the end of
the experiment (Figure 1Bii).
The numbers of E. coli that grew on MacConkey agar with
0.5 mg/L enroﬂoxacin (mutation rate) increased to around half
of the total E. coli at the second day upon the treatment of
enroﬂoxacin and remained at this level during the ﬁrst course
of the treatment. E. coli strains with mutation disappeared during
the antibiotic withdrawal period and reappeared during the sec-
ond course of treatment albeit at a lower level. E. coli strains with
mutation increased to a high level at the second day of the third
course of treatment, then decreased and reappeared again during
the antibiotic cessation period (Figure 1Biii). The data showed
that mutation in E. coli might mainly triggered by antibiotic treat-
ment and release of the antibiotic pressure can reduce the numbers
of E. coli with mutation, which suggested that without antibiotic
pressure, the E. coli with mutation may be less competitive than
other normal E. coli in animal GI tract. The long term antibiotic
treatment may make E. coli with mutation to adapt to animal GI
tract, which can be seen from the increased number of E. coli with
mutation at the end of third course of antibiotic treatment and
the following cessation period.
EFFECT OF SUB-THERAPEUTIC AND LOWER DOSES OF ANTIBIOTIC
TREATMENT ON RAT GI TRACT E. coli
Similar to the effect of the therapeutic dose of antibiotic treatment,
sub-therapeutic dose of enroﬂoxacin did not have any impact
on the overall numbers of E. coli in rat GI tract (Figure 1Ci).
The less susceptible E. coli strains emerged upon antibiotic treat-
ment and remained at a stable level throughout the course of the
experiment (Figure 1Cii). The numbers of GI tract E. coli with
target mutation slightly increased upon antibiotic treatment and
disappeared during the antibiotic cessation period for the ﬁrst
two courses of treatments. The mutation rate was signiﬁcantly
increased in E. coli upon the third course of antibiotic treatment
(Figure 1Ciii).
For the lower-level antibiotic treatment groups, namely 1/100
and 1/1000 of the therapeutic doses, no change in the number
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FIGURE 1 | Effect of different doses of enrofloxacin treatment on
mutation development in rat GI tract E. coli. (A) high dose (10-fold
therapeutic dose) enroﬂoxacin treatment, (B) therapeutic dose of enroﬂoxacin
treatment, (C) sub-therapeutic dose (1/10 of therapeutic dose) of enroﬂoxacin
treatment, (D) Low dose (1/100 of therapeutic dose) enroﬂoxacin treatment,
(E) very low dose (1/1000 of therapeutic dose) of enroﬂoxacin treatment, (F)
Control group; (i) Levels of rat GI tract E. coli during enroﬂoxacin treatment;
(ii) levels of less susceptible (grown on MacConkey supplemented with
0.125 mg/L of enroﬂoxacin) GI tract E. coli during enroﬂoxacin treatment;
(iii) Levels of rat GI tract E. coli with target mutation (grown on MacConkey
supplemented with 0.5 mg/L of enroﬂoxacin) during enroﬂoxacin treatment.
Y-axis represents the ratio between less susceptible E. coli or E. coli with
target mutation versus overall GI tract E. coli. Positive day number represents
the antibiotic treatment duration, negative day number represents the
duration since the cessation of antibiotic, 0 represents the day of the
application of antibiotic and the fecal E. coli were isolated before the
antibiotic treatment at day 0. The number is the average of data from ﬁve rats
in the group.
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Table 1 | MIC of enrofloxacin and target mutation profiles of rat GI tract E. coli.
Animal
group
Origin of E. coli
(enrofloxacin
selective plates)
Number of
isolates
MIC range of
enrofloxacin
(mg/L)
Target mutations
GyrA
(No. of E. coli )
ParC
A* 0.125 mg/L 20 0.015∼0.06 Wt (20/20) Wt
0.5 mg/L 20 0.25∼1 S83L (20/20) Wt
B 0.125 mg/L 20 0.015∼0.06 Wt (20/20) Wt
0.5 mg/L 20 0.25∼1 S83L (20/20) Wt
C 0.125 mg/L 20 0.015∼0.5 Wt (17/20),
S83L (3/20)
Wt
0.5 mg/L 20 0.25∼1 S83L (20/20) Wt
D 0.125 mg/L 20 0.06∼0.5 Wt (15/20),
S83L (5/20)
Wt
0.5 mg/L 20 0.125∼1 S83L (20/20) Wt
E 0.125 mg/L 20 0.06∼1 Wt (11/20),
S83L (9/20)
Wt
0.5 mg/L 20 0.125∼1 S83L (20/20) Wt
*A, high dose (10-fold therapeutic dose) enroﬂoxacin treatment; B, therapeutic dose of enroﬂoxacin treatment; C, sub-therapeutic dose (1/10 of therapeutic dose) of
enroﬂoxacin treatment; D, low dose (1/100 of therapeutic dose) enroﬂoxacin treatment; E, very low dose (1/1000 of therapeutic dose) of enroﬂoxacin treatment.
of GI tract E. coli could be observed throughout the experiment
(Figures 1Di,Ei). The less susceptible E. coli could be selected
during the second and third courses of antibiotic treatment and
the E. coli with mutation could also be selected during second and
third courses of the antibiotic treatments, with a higher rate at
the end of the third course of the treatment, suggesting long term
antibiotic treatment is the major trigger for the development of
resistance in GI tract E. coli (Figures 1Dii,Diii,Eii,Eiii). For the
control group, neither less susceptible E. coli nor E. coli with target
mutation could be selected (Figure 1F). Throughout the whole
experiment, no E. coli that can grow on 2 mg/L of enroﬂoxacin
could be obtained (data not shown).
Each of 20 E. coli isolates that grew on MacConkey with
0.125 mg/L and 0.5 mg/L enroﬂoxacin from different treatment
experiments were selected to check their MIC and target mutation
proﬁles. Different from the results obtained from the high dose
treatment group, E. coli that grew onMacConkey with 0.125 mg/L
enroﬂoxacin showed MIC range of enroﬂoxacin of 0.015∼0.5, a
little bit higher MIC than E. coli from high dose treatment group,
with nomutation on any of the four target genes gyrA, gyrB, parC,
and parE for most of the strains, but not all strains; on the other
hand, E. coli that grew on MacConkey with 0.5 mg/L enroﬂoxacin
exhibitedMIC of enroﬂoxacin of 0.25∼1mg/Lwith a singlemuta-
tion on GyrA (S83L) and no mutation at other target genes for all
test strains, similar to the results from high dose treatment group
(Table 1). The results further conﬁrmed the use of MacConkey
platewith 0.5mg/L enroﬂoxacin as a tool to check for themutation
rate of GI tract E. coli upon antibiotic treatment.
DISCUSSION
Improper uses of antibiotics from clinical applications and pro-
motion of animal growth are the main causes for high prevalence
of antimicrobial resistance in bacterial pathogens (Kelly et al.,
2004; Marshall and Levy, 2011; Looft et al., 2012). Evidences have
shown that in-feed use of antibiotics could dramatically lead to
an increase in the number of antimicrobial resistant genes and the
size of microbial ﬂora pool in anima GI tract (Looft et al., 2012).
Oral usage of antibiotics may be the direct route that facilitates
the selection of antimicrobial resistant gene and bacteria pool in
animal GI tract (Zhang et al., 2013). These studies reinforced the
concept that the antibiotic pressure in animal GI tract favored
the ampliﬁcation of antibiotic-resistant bacterial pool and cause
it to become dominant in the animal GI tract, therefore increas-
ing both antibiotic-resistant gene and bacteria pool. This study
focuses mainly on the understanding of how GI tract bacteria, in
particular E. coli, develop resistance upon encountering different
levels of antibiotic pressure.
To obtain meaningful interpretation of the data, all rats were
checked for the initial load of GI tract E. coli and their back-
ground level of susceptibility to enroﬂoxacin. Five rats with a
predominant background of low level resistance to enroﬂoxacin
(grow at MacConkey with 0.5 mg/L, but not with 2 mg/L)
were arranged into one group and treated with high dose of
enroﬂoxacin to check whether high dose of antibiotic could erad-
icate organisms with intermediate enroﬂoxacin resistance, while
other groups of mice with lower or no background of less resis-
tant E. coli were treated with different doses of antibiotic. This
study has come up with several conclusions that may be use-
ful for the understanding of bacterial resistance development
in animal GI tract. Firstly, high dose of antibiotic treatment
can eradicate less susceptible E. coli (with target mutation) and
prevent mutation development in E.coli in the early course of
enroﬂoxacin treatment, while became less effective for long term
treatment; therapeutic dose of enroﬂoxacin could select for the
www.frontiersin.org September 2014 | Volume 5 | Article 468 | 5
Lin et al. Respone of GI tract E. coli to antibiotics
less susceptible E. coli and those containing target mutations. It is
commonly accepted that intake of therapeutic dose of antibiotics
for the whole course of treatment could prevent the development
of resistance in bacterial pathogens. Our data showed that only
high dose of antibiotic could effectively eliminate E. coli with
target mutation, which are present in rat GI tract before treat-
ment. However, therapeutic dose, 1/10 and 1/100 of therapeutic
doses of enroﬂoxacin could select for less susceptible E. coli with-
out target mutation and E. coli with de novo target mutation.
Extremely low dose of enroﬂoxacin treatment, such as 1/1000
of therapeutic dose, can also select for less susceptible E. coli
without target mutation and E. coli with de novo target muta-
tion, but with lower efﬁciency. From the data obtained, we can
also see that most of the target mutations in E. coli were selected
during the later course of antibiotic treatment and antibiotic ces-
sation periods. Long term antibiotic treatment seems to be the
major trigger for the development of target mutations in GI tract
E. coli. Another interesting ﬁnding for this study is that antibi-
otic treatment, except for those with high dosage, did not affect
the total number of GI tract E. coli. Even under high dosage
antibiotic treatment, the number of GI tract E. coli decreased
upon treatment and then became normal even during the second
treatment.
Recent studies have reported the selection of resistant bacte-
ria under very low concentration of antibiotics in vitro (Gullberg
et al., 2011). However, these studies mainly focus on determining
the concentration of antibiotics that allow the resistant bacteria
to compete with their drug-susceptible counterparts favorably.
In another word, how concentration of antibiotics lower than
the MIC of susceptible cells, namely sub-MIC levels, promotes
the enrichment of resistant bacteria. One previous study also
showed how low concentration of antibiotic selects for de novo
resistant mutants (Gullberg et al., 2011). The selection process
in such study was antibiotic dependent. At 1 μg/ml concentra-
tion of streptomycin, Salmonella could develop resistance to up
to 128 μg/ml of streptomycin after 700 generations, whereas at
2.3 ng/ml of ciproﬂoxacin, E. coli could be selected at 184 ng/ml,
but not resistant to ciproﬂoxacin after 600 generations (Gullberg
et al., 2011). Similar to in vitro studies, our data showed that
regardless of the dosages of the enroﬂoxacin within three courses
of treatment and cessation regimen, no enroﬂoxacin-resistant
(MIC ≥4 mg/L) E. coli could be selected. In addition, no dou-
ble target mutations in gyrA or parC could be detected in E. coli
that could grow on MacConkey with 0.5 mg/L enroﬂoxacin. Our
data is consistent with an early study in chicken in which treat-
ment with enroﬂoxacin at doses routinely prescribed (50 ppm)
rapidly reduced the fecal counts of colonized E. coli below the
detection limit and did not induce resistance, whereas high fre-
quencies of ﬂuoroquinolone-resistant colonized C. jejuni were
selected due to the de novo mutation at the target genes (van
Boven et al., 2003). E. coli with S83, D87, or both mutations
have commonly been reported in in vitro selection experiments
and contributed to ﬂuoroquinolone resistance in E. coli (Vashist
et al., 2009). However, in the GI tract, no E. coli with resis-
tant to enroﬂoxacin could be selected and only E. coli with
reduced susceptibility to enroﬂoxacin and S83F target muta-
tion could be selected, which is probably due to the unique GI
environment. These data suggested that the generation of dou-
ble target mutations in GyrA and/or ParC, which is the major
mechanism of ﬂuoroquinolone resistance in E. coli, may be asso-
ciated with a ﬁtness cost that hampers its survival in animal GI
tract (Komp Lindgren et al., 2005; Gualco et al., 2007). In our
current research design, we were not able to select enroﬂoxacin-
resistant E. coli in mice GI tract. The fact that the high prevalence
of ﬂuoroquinolone-resistant E. coli in animal GI tract may be
due to the long term selection under antibiotic selective pres-
sure in animal gut or colonization of ﬂuoroquinolone-resistant
E. coli that has been selected outside the animal gut. Lastly, the
development of enroﬂoxacin-resistant E. coli in animal GI tract
may possibly require the acquisition of plasmid mediated resis-
tance determinant, which may further facilitate the development
of target mutation and therefore development of enroﬂoxacin
resistance in E. coli. Recent study has shown the high carriage
of different PMQR genes in animal E. coli isolates, which con-
tribute to the development of enroﬂoxacin resistance in E. coli
(Zhao et al., 2010; Yang et al., 2014). Different hypotheses of how
GI tact E. coli development resistance to ﬂuoroquinolone require
further investigations.
In conclusion, this study demonstrated that long term antibi-
otic treatment seems to be the major trigger for the development
of target mutations in GI tract E. coli, which provided insights into
the rational use of antibiotics in animal husbandry.
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